Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 14 studies | 39% ± 15% | |
astrocyte | 12 studies | 33% ± 16% | |
type I pneumocyte | 7 studies | 30% ± 9% | |
endothelial cell | 7 studies | 25% ± 8% | |
adipocyte | 7 studies | 30% ± 7% | |
oligodendrocyte precursor cell | 6 studies | 25% ± 8% | |
epithelial cell | 4 studies | 42% ± 14% | |
retinal cone cell | 4 studies | 26% ± 6% | |
cardiac muscle cell | 4 studies | 18% ± 2% | |
GABAergic neuron | 3 studies | 28% ± 9% | |
Mueller cell | 3 studies | 23% ± 4% | |
retinal rod cell | 3 studies | 23% ± 3% | |
club cell | 3 studies | 22% ± 5% | |
endothelial cell of lymphatic vessel | 3 studies | 19% ± 2% | |
fibroblast | 3 studies | 24% ± 8% | |
smooth muscle cell | 3 studies | 19% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 2114.19 | 245 / 245 | 100% | 12.55 | 502 / 502 |
breast | 100% | 2469.99 | 459 / 459 | 100% | 26.06 | 1116 / 1118 |
esophagus | 100% | 2444.44 | 1445 / 1445 | 99% | 12.13 | 182 / 183 |
uterus | 100% | 3007.81 | 170 / 170 | 99% | 11.45 | 456 / 459 |
skin | 100% | 2150.10 | 1808 / 1809 | 99% | 30.44 | 469 / 472 |
brain | 100% | 2620.63 | 2640 / 2642 | 99% | 13.14 | 699 / 705 |
ovary | 100% | 2339.64 | 180 / 180 | 99% | 12.03 | 424 / 430 |
bladder | 100% | 2405.76 | 21 / 21 | 98% | 10.77 | 496 / 504 |
liver | 100% | 1179.86 | 226 / 226 | 98% | 9.52 | 398 / 406 |
stomach | 100% | 1740.48 | 359 / 359 | 98% | 9.76 | 280 / 286 |
lung | 100% | 2466.52 | 578 / 578 | 98% | 12.00 | 1130 / 1155 |
intestine | 100% | 2578.35 | 966 / 966 | 97% | 8.33 | 512 / 527 |
thymus | 100% | 2425.30 | 652 / 653 | 97% | 11.92 | 584 / 605 |
kidney | 100% | 1266.01 | 89 / 89 | 94% | 8.78 | 848 / 901 |
pancreas | 94% | 800.68 | 309 / 328 | 99% | 10.17 | 176 / 178 |
adrenal gland | 100% | 2328.21 | 258 / 258 | 90% | 5.49 | 207 / 230 |
adipose | 100% | 2484.70 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2938.24 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 13.59 | 80 / 80 |
muscle | 100% | 3508.54 | 803 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 10.06 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 13.01 | 1 / 1 |
spleen | 100% | 1067.91 | 240 / 241 | 0% | 0 | 0 / 0 |
heart | 96% | 1392.84 | 824 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 34% | 1.45 | 10 / 29 |
peripheral blood | 25% | 367.62 | 230 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0071108 | Biological process | protein K48-linked deubiquitination |
GO_0001701 | Biological process | in utero embryonic development |
GO_0002385 | Biological process | mucosal immune response |
GO_0071947 | Biological process | protein deubiquitination involved in ubiquitin-dependent protein catabolic process |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0002250 | Biological process | adaptive immune response |
GO_0070536 | Biological process | protein K63-linked deubiquitination |
GO_0006508 | Biological process | proteolysis |
GO_0032717 | Biological process | negative regulation of interleukin-8 production |
GO_1900181 | Biological process | negative regulation of protein localization to nucleus |
GO_0035871 | Biological process | protein K11-linked deubiquitination |
GO_0043124 | Biological process | negative regulation of canonical NF-kappaB signal transduction |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0070530 | Molecular function | K63-linked polyubiquitin modification-dependent protein binding |
GO_0004843 | Molecular function | cysteine-type deubiquitinase activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_1990380 | Molecular function | K48-linked deubiquitinase activity |
GO_0008234 | Molecular function | cysteine-type peptidase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | OTUD7B |
Protein name | OTU domain-containing protein 7B (EC 3.4.19.12) (Cellular zinc finger anti-NF-kappa-B protein) (Cezanne) (Zinc finger A20 domain-containing protein 1) (Zinc finger protein Cezanne) ubiquitinyl hydrolase 1 (EC 3.4.19.12) |
Synonyms | ZA20D1 RP11-212K13.2-003 |
Description | FUNCTION: Negative regulator of the non-canonical NF-kappa-B pathway that acts by mediating deubiquitination of TRAF3, an inhibitor of the NF-kappa-B pathway, thereby acting as a negative regulator of B-cell responses. In response to non-canonical NF-kappa-B stimuli, deubiquitinates 'Lys-48'-linked polyubiquitin chains of TRAF3, preventing TRAF3 proteolysis and over-activation of non-canonical NF-kappa-B. Negatively regulates mucosal immunity against infections (By similarity). Deubiquitinates ZAP70, and thereby regulates T cell receptor (TCR) signaling that leads to the activation of NF-kappa-B . Plays a role in T cell homeostasis and is required for normal T cell responses, including production of IFNG and IL2 (By similarity). Mediates deubiquitination of EGFR . Has deubiquitinating activity toward 'Lys-11', 'Lys-48' and 'Lys-63'-linked polyubiquitin chains . Has a much higher catalytic rate with 'Lys-11'-linked polyubiquitin chains (in vitro); however the physiological significance of these data are unsure . Hydrolyzes both linear and branched forms of polyubiquitin. . |
Accessions | Q5SZ59 ENST00000417191.2 Q6GQQ9 ENST00000581312.6 [Q6GQQ9-1] |